KURA Q4 2018 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena

KURAKura Oncology, Inc.

$774M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M100.0% margin

Operating Income

-$17M-682.8% margin

Net Income

-$16M-660.8% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$182M

Total Liabilities

$21M

Stockholders' Equity

$161M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	$0	—
Operating Income	-$17M	-$11M	-51.3%
Net Income	-$16M	-$11M	-49.8%